Deep Bio, a leader in artificial intelligence for digital pathology, announced a collaboration to integrate its prostate ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Siriraj Piyamaharajkarun Hospital (SiPH), operating under Faculty of Medicine Siriraj Hospital, today announced a successful ...

BRCA mutations are inextricably linked with breasts, but they can also lead to cancer in the pancreas, the prostate, and ...

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence (AI) method ...

Alverno, a joint venture between Franciscan Health and Ascension Illinois, is using the Phillips IntelliSite Pathology ...

Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The scientists found that the absence of a protein called PKCλ/ι in ...

Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and published Nov. 20 in Nature Communications, found that the absence ...